BioXcel Therapeutics, Inc. (BTAI)

Market Cap	7.17M
Revenue (ttm)	2.28M
Net Income (ttm)	-71.00M
Shares Out	3.10M
EPS (ttm)	-31.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,016
Open	2.290
Previous Close	2.180
Day's Range	2.120 - 2.370
52-Week Range	1.720 - 49.580
Beta	0.90
Analysts	Buy
Price Target	42.60 (+1,744.16%)
Earnings Date	Mar 27, 2025

About BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI
• Website: https://www.bioxceltherapeutics.com

Financial Performance

In 2023, BioXcel Therapeutics's revenue was $1.38 million, an increase of 268.00% compared to the previous year's $375,000. Losses were -$179.05 million, 8.02% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $42.6, which is an increase of 1,744.16% from the latest price.

Price Target

$42.6

(1,744.16% upside)

Analyst Consensus: Buy